by Maria Zannes | Mar 6, 2024 | Press Releases
bioAffinity Technologies Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement SAN ANTONIO, Texas (March 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF and BIAFW) today announced it has entered into a securities...
by Maria Zannes | Mar 5, 2024 | Press Releases
Increasing physician interest, newly approved reimbursement code driving growth SAN ANTONIO, Texas (March 5, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of...
by Maria Zannes | Feb 21, 2024 | Press Releases
SAN ANTONIO, Texas (Feb. 21, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news. Lung...
by Maria Zannes | Feb 6, 2024 | Press Releases
Medical Director of Pennsylvania’s Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies’ Medical and Scientific Advisory Board and Incorporates CyPath® Lung into Medical Practice SAN ANTONIO,...
by Maria Zannes | Jan 30, 2024 | Press Releases
SAN ANTONIO, Texas (Jan. 30, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provides a summary of recent Company news. Precision...
